Acomplia Rimonabant, Zimulti News For 2008
Sanofi to Present More Acomplia Data at April 11th Meeting
Sanofi-Aventis, developer of the highly publicized anti–obesity drug Acomplia, will present new data on the drug’s role in reducing metabolic cardiovascular disease risk factors at a scientific meeting in San Diego April 11th and 12th.
Dr. Pierre Rosenzweig, a Vice President of Sanofi-Aventis, will make the presentation at the Annual Metabolic [...]
Report in The Lancet Further Boosts Interest in Weight-Loss Drug Acomplia
A report published in this week’s issue of the prestigious medical journal, The Lancet, further stoked interest in the promising new weight-loss drug Acomplia (rimonabant) but in fact provided little new information.
The report was based on one-year results from the RIO–Europe clinical trial, which showed [...]
Support for “Metabolic Syndrome” May Buttress Expanded Role for Acomplia
The American Heart Association (AHA) and the National Heart, Lung and Blood Institute (NHLBI) on Sept. 13 issued a new scientific statement taking issue with two major diabetes organizations Acomplia (rimonabant) that a month ago questioned the validity of diagnosing patients with “metabolic syndrome.”
The debate could well impact efforts of [...]
FDA Advisory Panel Says Obese Kids Should Be Included in Drug Trials
A U.S. FDA Advisory Committee reviewing guidelines for weight-loss drug trials appear prepared to call for studies that focus on the effect of anti–obesity drugs on severely obese children Acomplia (rimonabant) .
Acomplia (rimonabant) “This population of patients needs to be studied separately from the [...]
Experimental Obesity Drug APD356 Reported Effective in Small, Short Trial
A year ago at this time, millions of overweight and obese An experimental drug for the treatment of obesity, APD356, reportedly produced encouraging results in a relatively small four week clinical trial, according to a statement released by Arena Pharmaceuticals, Inc Acomplia (rimonabant) .
Arena said [...]
Survey: Two Thirds of Doctors Likely to Prescribe Acomplia for Obesity
Two out of three doctors say they are likely to prescribe Acomplia (rimonabant) to treat patients with obesity after the new drug is approved by the U.S. Food and Drug Administration, according to a new research study.
Decision Resources, Inc., a leading research and advisory firm [...]
Roche, GlaxoSmithKline Sign Promotional Agreement for Xenical in U.S.
Pharmaceutical giants Roche and GlaxoSmithKline have signed a promotional agreement for weight-loss medication Xenical (orlistat) in the United States, according to a statement issued April 12th.
The pact gives Glaxo exclusive rights to promote prescription Xenical in the United States. Glaxo also acquired the rights to an over-the-counter (OTC) version of the [...]
New Acomplia News Will Be Presented on March 8th
After a four-month dry spell during which there has been little news about development of the highly publicized obesity drug Acomplia (rimonabant) , researchers are scheduled to present new data from the RIO–Europe clinical trial at a scientific meeting in Orlando on Tuesday, March 8th.
The presentation of the [...]
